At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 125 enrolled
Drug / intervention
Nilotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
In Brief
A Phase 3 clinical trial evaluating Nilotinib for Gastrointestinal Stromal Tumors. Completed, enrolled 125 participants across 19 sites in 2 countries.
Detailed Summary
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesGermany, Italy
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedFeb 2011
Primary CompletionJul 2014
TodayJul 2026
First PostedFeb 3, 2011
Enrollment StartNov 1, 2008
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 15.4 years ago
Interventions
Nilotinibdrug